FiercePharmaOriginal article
{"a":[{"_":"Novo Nordisk’s Wegovy helps free 40% of kids from obesity in phase 3 trial","$":{"href":"/pharma/novo-nordisks-wegovy-helps-free-40-kids-obesity-phase-3-trial","hreflang":"en"}}]}
Phase 3positiveWegovyPositive
AI Analysis
Summary
Novo Nordisk reported positive Phase 3 trial results for Wegovy in children with obesity, with 40% of participants no longer classified as obese after 68 weeks of treatment.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
40% of children (2 out of 5) no longer classified as having obesity after 68 weeks of treatment
Importance:7/10
Sentiment:
0.80
GLP-1weight managementpediatricobesity
Related Companies
Read the original article
Published by FiercePharma on September 8, 2026 10:02 AM